New itch relief pill tested for dialysis patients
NCT ID NCT07650851
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a tablet called nalfurafine hydrochloride to treat severe itching in people on maintenance hemodialysis for chronic kidney disease. About 150 adults will take the tablet once daily for 12 weeks. Researchers will measure changes in itching severity using a visual scale and track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nalfurafine hydrochloride
What this could lead to
If it works, this could provide a new option to relieve severe itching in people on dialysis, improving their quality of life.
What could go wrong
This is an early-stage study with no phase designation, so results are uncertain. The drug may not reduce itching more than standard care, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS IN HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••